

# Functional site of endogenous phospholipase A<sub>2</sub> inhibitor from python serum

## Phospholipase A<sub>2</sub> binding and anti-inflammatory activity

Maung-Maung Thwin<sup>1</sup>, Ramapatna L. Satish<sup>2</sup>, Steven T. F. Chan<sup>2</sup> and Ponnampalam Gopalakrishnakone<sup>1</sup>

Venom and Toxin Research Programme, Departments of <sup>1</sup>Anatomy and <sup>2</sup>Surgery, Faculty of Medicine, National University of Singapore, Singapore

The functional site of 'phospholipase A<sub>2</sub> inhibitor from python' (PIP) was predicted based on the hypothesis of proline brackets. Using different sources of secretory phospholipase A<sub>2</sub> (sPLA<sub>2</sub>s) as enzyme, and [<sup>3</sup>H]arachidonate-labelled *Escherichia coli* as substrate, short synthetic peptides representing the proposed site were examined for their secretory phospholipase A<sub>2</sub> (sPLA<sub>2</sub>) inhibitory activity. A decapeptide P-PB.III proved to be the most potent of the tested peptides in inhibiting sPLA<sub>2</sub> enzymatic activity *in vitro*, and exhibited striking anti-inflammatory effects *in vivo* in a mouse paw oedema model. P-PB.III inhibited the enzymatic activity of class I, II and III PLA<sub>2</sub>s, including that of human synovial fluid from arthritis patients. When tested by ELISA, biotinylated P-PB.III interacted positively with various PLA<sub>2</sub>s, suggesting that the specific region of PIP

corresponding to P-PB.III, is likely to be involved in the PLA<sub>2</sub>-PLI interaction. The effect of P-PB.III on the peritoneal inflammatory response after surgical trauma in rats was also examined. P-PB.III effectively reduced the extent of postsurgical peritoneal adhesions as compared to controls. sPLA<sub>2</sub> levels at seventh postoperative day in the peritoneal tissue of P-PB.III-treated rats were also significantly reduced ( $P < 0.05$ ) in comparison to those of the untreated controls. The present results shed additional insight on the essential structural elements for PLA<sub>2</sub> binding, and may be useful as a basis for the design of novel therapeutic agents.

**Keywords:** anti-inflammatory peptide; phospholipase inhibitor from python PIP; protein-protein interaction; phospholipase A<sub>2</sub> inhibitors; postsurgical adhesions.

Secretory phospholipases A<sub>2</sub> (sPLA<sub>2</sub>s) are enzymes (EC.3.1.1.4) that catalyse the hydrolysis of the *sn*-2 acyl bond of glycerophospholipids to produce free fatty acids and lysophospholipids [1], and are implicated in a range of diseases associated with inflammatory conditions such as arthritis, peritonitis, etc. [2–5]. Furthermore, PLA<sub>2</sub> inhibitors (PLIs) have recently become the subject of much interest due to the potential benefits they could offer in the treatment of inflammation and cell injury.

A number of PLIs have been purified and characterized from a variety of sources, including plant, fungi, and bacteria [6–8]. PLIs that interact with PLA<sub>2</sub>s and inhibit their enzymatic activity have been identified in the sera of venomous snakes belonging to Elapidae and Crotalidae families [9–20]. The discovery of specific sPLA<sub>2</sub> inhibitors has also been reported in the blood serum of nonvenomous snakes [21,22]. These studies have demonstrated the

presence of three different types of PLIs ( $\alpha$ ,  $\beta$  and  $\gamma$ ) in the sera of snakes, which are believed to have a natural defensive role against endogenous snake venom sPLA<sub>2</sub>s.

Our recent cloning and expression study has revealed that the PLI termed 'phospholipase inhibitor from python (PIP)' possesses potent nonspecies specific antitoxic and anti-inflammatory activities, which have been linked to its ability to inhibit sPLA<sub>2</sub> [22]. This inhibitor signifies structural homology with other  $\gamma$ -type snake PLIs [12,14,18] and various mammalian proteins belonging to the 'three fingers' neurotoxin superfamily, including the urokinase-type plasminogen-activator receptor, membrane proteins of the Ly-6 family, and a bone-specific protein RoBo-1 [12,23].

On the basis of sequence homology study, some groups have been able to identify short peptides that act as a surrogate for the larger molecule [24], and their usefulness as potential anti-inflammatory agents have been reported [25]. Short peptides called antinflamins that are synthesized based on the region of highest homology between uteroglobin and lipocortin I, have previously been shown to inhibit PLA<sub>2</sub> [24,25], although there are some reports suggesting that these antinflamins are devoid of PLA<sub>2</sub> inhibitory activity [26,27]. Recently, the importance of proline brackets flanking protein-protein interaction sites has been emphasized in identifying potential functional sites in proteins [28]. Following this hypothesis, we were able to identify the active site on PIP that binds to sPLA<sub>2</sub>s potently in a nonspecies-specific manner. In the present study, a short oligopeptide, corresponding to the segment of the hypothetical interaction site has been synthesized and examined for its anti-inflammatory activity and PLA<sub>2</sub> binding, with a

Correspondence to P. Gopalakrishnakone, Department of Anatomy, Faculty of Medicine, 4 Medical Drive, National University of Singapore, Singapore 117597. Fax: + 65 7787643, E-mail: antgopal@nus.edu.sg

**Abbreviations:** PLA<sub>2</sub>, phospholipase A<sub>2</sub>; AIP, anti-inflammatory peptide; IC<sub>50</sub>, concentration of the inhibitor that inhibits PLA<sub>2</sub> activity by 50%; PIP, phospholipase inhibitor from python; PLI, phospholipase A<sub>2</sub> inhibitor; sPLA<sub>2</sub>, secretory phospholipase A<sub>2</sub>. **Note:** a web site is available at <http://www.med.nus.edu.sg/ant/anatomy.htm>

(Received 22 August 2001, revised 30 October 2001, accepted 29 November 2001)

view to locate the particular region on PLIs that is responsible for binding to PLA<sub>2</sub>.

## EXPERIMENTAL PROCEDURES

### Materials

All the venoms and PLA<sub>2</sub> toxins used in the experiments were available from the VTRP (Venom and Toxin Research Programme) collections, except for the bee (*Apis mellifera*) venom PLA<sub>2</sub> which was purchased from Sigma Chemical Co. (St Louis, MO, USA). Anti-inflammatory peptide 2 (antiflammin 2), *o*-phenylenediamine dihydrochloride ([2-(biotinamido)ethylamido]-3,3'-dithiodipropionic acid *N*-hydroxysuccinimide ester, and avidin-peroxidase conjugate were purchased from Sigma. UniverSol ES liquid scintillation cocktail was from ICN Biomedicals, Inc., USA; Hylan GF 20 (Synvisc) gel was purchased from Bayer Pte. Ltd (Singapore). All other reagents were of analytical grade or better.

### Animals

Swiss albino mice (20–25 g) used for paw oedema assay and the Sprague–Dawley rats (250–320 g) used in the incisional hernia model were purchased from the Laboratory Animals Centre, Sembawang, Singapore, and housed in the Animal Holding Unit of the Department of Anatomy, National University of Singapore for 2 weeks to acclimatize the animals prior to use. Water and food (Glen Forrester Stockfeeders, WA, Australia) were provided *ad libitum* and a 12-h light/12-h dark cycle was maintained. The animals were handled according to the Guidelines of the National Medical Ethics Committee (Singapore), which conform to the World Health Organization's International Guiding Principles for Animal Research [29].

### Peptide synthesis

The peptides with the sequences LSLQNGLY and PGLPLSLQNG, designated P-PB.II and PB.III, respectively, were custom-synthesized at the Biotechnology Processing Centre, National University of Singapore, by conventional solid phase techniques using automated ABI 4338 Peptide Synthesizer. The test peptide, designated P-PB.I with the sequence LPGLPLSLQNGLY, and the control peptide designated SP-PB.III, containing the same amino-acid composition as that of P-PB.III, but with the scrambled sequence, QLNPLPGLGS, were synthesized at the Fukuoka Women's University, Japan. All the synthetic peptides were purified by RP-HPLC to more than 95% purity, with yields between 85 and 90%. The sequences were validated by MALDI-MS (Voyager-DESTRO BioSpectrometry Workstation).

### SPLA<sub>2</sub> assay with [<sup>3</sup>H]arachidonate-labelled *E. coli*

Enzyme activity was assayed according to the described method [30] with minor modifications. Briefly, the reaction mixture contained 200 µL of assay buffer (100 mM Tris/HCl pH 7.5, 25 mM CaCl<sub>2</sub>), 20 µL of [<sup>3</sup>H]arachidonate-labelled *E. coli* suspension (0.005 mCi·mL<sup>-1</sup>; 5.8 µCi·µmol<sup>-1</sup>, NEN) and 30 µL (10 ng) of daboia toxin, crotoxin

subunit B, β-bungarotoxin, bee venom PLA<sub>2</sub> (Sigma, 1360 U·mg<sup>-1</sup>), or human synovial fluid, in a total volume of 250 µL. After incubation of the mixture (37 °C, 1 h) and termination of the reaction with 750 µL of chilled NaCl/P<sub>1</sub> containing 1% BSA, the microfuge tubes containing the samples were centrifuged (10 000 g, 4 °C) for 15 min, and 500-µL aliquots of the supernatant taken to measure the amount of <sup>3</sup>H-labelled arachidonate released from the *E. coli* membrane using liquid scintillation counting (Multipurpose Scintillation Counter LS 6500; Beckman). Appropriate controls without PLA<sub>2</sub> were also included in the assays. To determine the inhibitory activity, daboia toxin or different source of PLA<sub>2</sub>s was preincubated for 1 h at 37 °C with each peptide at varying concentrations (1–250 µM), before addition of the *E. coli* substrate suspension. As controls for the inhibition assays, PLA<sub>2</sub> was preincubated with the assay buffer. All samples, including the controls, were performed in triplicate and plotted as the percentage inhibition relative to negative controls.

### IC<sub>50</sub> determination

IC<sub>50</sub> was determined by preincubating varying concentrations (1–250 µM) of peptides in a constant volume, against a constant amount of enzyme as described earlier. A sigmoid dose–response curve was generated to allow calculation of the IC<sub>50</sub> values. All samples were performed in triplicate. Results were analyzed by nonlinear regression with GraphPad PRISM (version 2.01) and expressed as the percentage of inhibition relative to control values.

### Biotinylation of peptide

Five-hundred micrograms of peptide P-PB.III (0.36 µmol) was dissolved in 1 mL of 0.1 M NaHCO<sub>3</sub> pH 7.5, and the biotinylation reaction was initiated by addition of 60 µL (1.08 µmol) of the biotin disulfide *N*-hydroxysuccinimide ester solution to the peptide solution. The molar ratio of the peptide to biotin used in the reaction was 1 : 3. After incubation of the reaction mixture at 25 °C for 1 h, the reaction was stopped, and unreacted biotinylating agent was removed by dialyzing against 2-L volumes of NaCl/P<sub>1</sub> (three changes) at 4 °C using Spectra/Por6 membrane (molecular mass cutoff 1000; SPECTRUM Medical Industries, Inc.). To check the purity, the biotinylated P-PB.III was injected onto a Vydac C<sub>18</sub> RP-HPLC column and eluted with a linear gradient of solvent A (0.1% trifluoroacetic acid) and solvent B (100% acetonitrile/0.1% trifluoroacetic acid) at a flow rate of 1 mL·min<sup>-1</sup>. The column eluate was monitored at 215 nm and 1-min fractions were collected. In addition, HPLC-purified biotinylated P-PB.III was subjected to MS analysis.

### ELISA

Wells of microtitre plates (Dynex Technologies, Inc., USA) were coated overnight at 4 °C with 100 µL of different sources of either the venom (5 µg·mL<sup>-1</sup>) or PLA<sub>2</sub> (1 µg·mL<sup>-1</sup>) in 100 mM carbonate/bicarbonate buffer, pH 9.6. The controls wells were coated with buffer only. All washing steps were carried out at least three times with NaCl/P<sub>1</sub>/Tween throughout. The coated plates were washed, and unbound sites were saturated by incubating

for 1 h at 37 °C with 150 µL of 3% fat-free milk powder (Bio-Rad) in NaCl/P<sub>i</sub>/Tween. After washing, the wells were incubated with 100 µL of biotinylated P-PB.III (1 µg·mL<sup>-1</sup>) in NaCl/P<sub>i</sub>/Tween for 1 h at 37 °C, washed again and incubated further for 1 h at 37 °C with 100 µL of Avidin-peroxidase conjugate (Affinity purified, Sigma) at a dilution of 1 : 2000 in NaCl/P<sub>i</sub>/Tween. After washing, 100 µL of substrate solution (0.5 g·L<sup>-1</sup> *o*-phenylenediamine di-HCl/0.02% H<sub>2</sub>O<sub>2</sub>; Sigma) was added to each well and the enzymatic reaction stopped by adding 50 µL of 2 M H<sub>2</sub>SO<sub>4</sub> prior to reading the absorbance at 490 nm (Emax Precision Microplate Reader, Molecular Devices).

### Effect of active peptide on PLA<sub>2</sub>-induced mouse paw oedema

The oedema produced by the crude venom or purified PLA<sub>2</sub>s from *Daboia russelli siamensis* venom or bee venom, was assayed according to the method described [31]. Male Swiss albino mice (20–25 g) in groups of four were injected subcutaneously into the footpad of the left hind paw with the indicated amounts of venom or PLA<sub>2</sub>s (5 µg venom; 1 µg daboitoxin or bee venom PLA<sub>2</sub>) in a total volume of 25 µL of sterile NaCl/P<sub>i</sub>. At 45 min thereafter, the mice were euthanized using CO<sub>2</sub> insufflation, and both hind limbs disarticulated at the ankle joint were individually weighed. The increase in weight due to oedema was calculated by subtracting the weight of each nontreated right hind limb. To study the effect on PLA<sub>2</sub>-induced paw oedema, venom (5 µg) or PLA<sub>2</sub>s (1 µg) were preincubated with varying concentrations of the inhibitors (PIP, 0.5, 1 nmol; P-PB.III, 50, 100 nmol; AIP-2, 92 nmol), in a total volume of 25 µL prior to injection. Inhibitory effects were assessed by comparing the paw oedema of inhibitor-treated groups to that of nontreated groups. Inhibitors alone or NaCl/P<sub>i</sub> alone were injected as controls.

### Effect of active peptide on postsurgical peritoneal adhesions

An *in vivo* incisional hernia model [32] was used to assess the potential therapeutic application of the active peptide P-PB.III in reducing the formation of postsurgical peritoneal adhesions in male Sprague–Dawley rats (250–320 g). Under light ether anesthesia and by means of a midline laparotomy incision, a ventral abdominal defect (15 × 25 mm) was created in each of the 30 rats, which were divided into four groups. The caecum was located, externalized and the serosal surface abraded, using dry gauze until subserosal punctate hemorrhage was seen. A polypropylene mesh (Surgipromesh, Autosuture Co.) was then sutured to the abdominal defect. Prior to closure of the abdominal skin, a hyaluronate-based gel (Hylan GF 20), either alone or with an anti-inflammatory peptide, was administered intraperitoneally over the abraded caecum. Group I (*n* = 12) contained only the mesh to serve as a control; group II (*n* = 6) contained exclusively the gel, while groups III (*n* = 6) and IV (*n* = 6) contained the gel spiked with 0.16 µmol each of the anti-inflammatory peptides, P-PB.III and AIP-2, respectively. On postoperative day 7, a re-laparotomy was performed and peritoneal adhesions were graded using a method previously described [33].

### Peritoneal tissue sPLA<sub>2</sub> activity

The peritoneal tissue specimens collected from each rat at day 0 and on postoperative day 7 were stored immediately at –80 °C until the time of analysis. Approximately 150–250 mg (wet weight) of the peritoneal tissues were weighed and homogenized in 2 mL of NaCl/P<sub>i</sub> using Heidolph DIAx900 homogeniser (Germany). Supernatant collected after centrifugation (20 000 *g*) at 4 °C for 20 min was used for measurement of total protein [34] and PLA<sub>2</sub> activity [30]. For each sample, the mean and standard deviations were obtained for replicates (*n* = 3).

### Statistical analysis

The results from the paw oedema experiment in mice were analyzed by a one-tailed Student's *t*-test for groups of unpaired observations. Significance was taken at *P* < 0.05. The statistical significance of the effects of the peptides was also confirmed by one-way ANOVA.

Wilcoxon rank sum test was used for analyzing differences in peritoneal tissue PLA<sub>2</sub> activity at two different time points, day 0 (at the time of surgery) and day 7 (after surgical trauma). The significance of the difference in the postoperative peritoneal tissue PLA<sub>2</sub> activity at day 7 between the P-PB.III-treated and untreated groups were analyzed by nonparametric Mann–Whitney *U*-test. A *P* value less than 0.05 was considered statistically significant.


## RESULTS

### PIP has significant amino-acid sequence homology with other snake PLIs

The nonredundant BLASTP alignment of the amino-acid sequence of a mature PIP monomer with the database sequences whose match satisfies the preset *E* value of 0.001 is shown in Fig. 1. The mature PIP protein contains 16 cysteine residues all of which align perfectly in the database matched sequences. It has the highest sequence identity (57–61%) to the mature PLIs from the sera of Crotalidae snakes, *Agkistrodon blomhoffii siniticus* [14], *Crotalus durissus terrificus* [11,13], and *Trimeresurus flavoviridis* (*Protobothrops flavoviridis*) [9,15], with sequence identities of 61, 60 and 57%, respectively. PIP also has a significant (57%) homology to the sequences of mature PLIs of a nonvenomous snake *Elaphe quadrivirgata* [21], and also to those of the PLIs from the sera of Australian Elapidae, *Notechis ater*, *Notechis scutatus*, and *Oxyuranus scutellatus* [19], with sequence identities in the vicinity of 56%.

### The potential interaction site on PIP is predicted by searching for proline residues that mark the flanks of protein–protein interaction sites

The amino-acid sequence of PIP (Fig. 1) shows four proline residues at positions 85, 87, 90 and 100. As the residues at position 85 and 100, and 90 and 100, respectively, served as the flanking prolines enclosing a small segment of the PIP in each case, we predicted that the segments, LPGLPLSLQNGLY (P-PB.I) and/or LSLQNGLY (P-PB.II), might indicate possible interaction site for PIP with sPLA<sub>2</sub>. Both these peptides displayed *in vitro* PLA<sub>2</sub> inhibitory activity, but



**Fig. 1.** Alignment of the mature PIP monomer with the database sequences. The *E* value was preset at 0.001 for matching the amino-acid sequences. The shaded boxes indicate residues identical to those of PIP. (1) *Python reticulatus* PIP; (2) *Agkistrodon blomhoffii siniticus* PLI $\gamma$ ; (3) *Crotalus d. terrificus* CNF; (4) *Protothrops flavoviridis* PLI $\gamma$ ; (5) *Elaphe quadri-virgata* PLI $\gamma$ ; (6) *Notechis ater*  $\alpha$  subunit isoform NAI-3 A; (7) *Notechis scutatus*  $\alpha$  chain iii; (8) *Oxyuramus scutellatus*  $\alpha$  subunit isoform OSI-1 A.

P-PB.I was the only peptide that was found to possess remarkable *in vivo* anti-inflammatory activity, while P-PB.II was less active. With P-PB.I being more active than P-PB.II, it was assumed that the bioactivity might be related mainly to that particular segment of PIP. The third peptide P-PB.III with the sequence PGLPLSLQNG, which represents the shorter segment of the proposed site, exhibited the strongest anti-PLA<sub>2</sub> and anti-inflammatory activities, while the scrambled peptide SP-PB.III was found to be totally devoid of PLA<sub>2</sub>-inhibitory activity (Table 1).

#### Synthetic peptides derived from the hypothetical interaction site inhibit PLA<sub>2</sub> enzyme activity and bind to sPLA<sub>2</sub>


The dose–response relationships for the synthetic peptides and the full-length recombinant PIP were determined and are shown in Fig. 2. The 13-residue peptide P-PB.I, which corresponds to PIP residues 86–98, is a strong inhibitor against the PLA<sub>2</sub> activity of daboia toxin (IC<sub>50</sub>

37.82 ± 2.40 μM), while the octapeptide P-PB.II, is less potent (IC<sub>50</sub> 45.09 ± 1.14 μM). Among the three synthetic peptides examined for PLA<sub>2</sub> inhibitory activity, the decapeptide P-PB.III, corresponding to PIP residues 87–96, is the strongest inhibitor that possesses PLA<sub>2</sub> inhibitory potency (IC<sub>50</sub> 22.65 ± 2.91 μM) equivalent to that of the recombinant inhibitor PIP (IC<sub>50</sub> 19.51 ± 2.06 μM). P-PB.III dose-dependently inhibits the enzyme activity of a variety of sPLA<sub>2</sub> sources from snakes, bee and human, over a wide concentration range (1–250 μM), while the scrambled peptide SP-PB.III, fails to inhibit sPLA<sub>2</sub> at any concentration tested. Biotinylation of the active peptide, P-PB.III does not seem to result in considerable loss of inhibitory potency as judged by similar IC<sub>50</sub> values obtained for the native P-PB.III (IC<sub>50</sub> = 22.6 ± 2.9 μM) and its biotinylated product (IC<sub>50</sub> = 25.8 ± 3.1 μM) in the binding assays.

The experimental evidence of the fact that P-PB.III interacts with sPLA<sub>2</sub> is demonstrated by ELISA and shown in Fig. 3. The purity of the biotinylated P-PB.III as evaluated by RP-HPLC was 95%, and the determined

**Table 1.** Amino-acid sequences and properties of peptides derived from the predicted site. Test peptides P-PB-I, II, III and the control scrambled peptide S-PB.III were synthesized by solid phase techniques. Experimental details are described in the Experimental procedures. PLA<sub>2</sub> inhibition indicates maximal enzyme inhibition towards daboia toxin seen at a fixed peptide concentration (100 μM). IC<sub>50</sub> values were calculated from the corresponding dose–response curves shown in Fig. 2, by nonlinear regression analysis with GraphPad PRISM (version 2.01). Anti-inflammatory activity was assessed by daboia toxin-induced mouse paw oedema experiments. Values reported are the mean of triplicate experiments.


Code no.	Sequence	Length	<i>M<sub>r</sub></i>	PLA <sub>2</sub> inhibition (%)	IC <sub>50</sub> (μM)	Anti-inflammatory activity
P-PB.I	LPGLPLSLQNGLY	13	1385	70.71	37.82	(+) moderate
P-PB.II	LSLQNGLY	8	1018	51.69	45.09	(-) negative
P-PB.III	PGLPLSLQNG	10	995	91.60	22.60	(+ +) strong
SP-PB.III	GLNPLPGLQS	10	995	0	–	Not tested



**Fig. 2. Phospholipase A<sub>2</sub> inhibition curves for PIP and various synthetic peptides.** (A) Inhibition profiles against daboia toxin PLA<sub>2</sub> activity: PIP (▼); PIP-derived test peptides, P-PB.III (○), P-PB.I (□), P-PB.II (△); control scrambled peptide, SP-PB.III (●); Biotinylated P-PB.III (■). (B) Inhibition profiles of the active peptide P-PB.III against enzymatic activity of various sources of sPLA<sub>2</sub> – β-bungarotoxin (△), crotoxin B (▼), bee venom PLA<sub>2</sub> (■), human synovial fluid (●). Results are the mean ± SD. IC<sub>50</sub> values were graphically determined from the inhibition curves, constructed on the basis of the *in vitro* results of <sup>3</sup>H-labelled *E. coli* membrane assays.

mass was 1118 Da. Based on the mass (998 Da) of the intact peptide and that of the biotinylated P-PB.III, 0.12 mol biotin was apparently bound to 1 mol of P-PB.III.

Most venoms and PLA<sub>2</sub>s examined, reacted positively with the biotinylated P-PB.III, although the results vary depending upon the type of PLA<sub>2</sub> used. P-PB.III interacts very strongly with group I PLA<sub>2</sub> toxin, β-bungarotoxin, but binds moderately to group II PLA<sub>2</sub> toxins like daboia toxin, mojave toxin subunit B, ammodytoxin A and crotoxin. It gives strong positive ELISA reaction with the enzymatically active basic subunit of crotoxin while its binding to the non-PLA<sub>2</sub> acidic subunit of crotoxin is negligible. Interestingly, the biotinylated peptide P-PB.III



**Fig. 3. Binding of P-PB.III to various sources of sPLA<sub>2</sub> in ELISA.** Biotinylated P-PB.III was directed against different sources of sPLA<sub>2</sub> or crude venom coated on microtitre plate wells. Bound biotinylated peptide in each well was detected with avidin-peroxidase conjugate and color development with a substrate solution as described in the Experimental procedures. All samples were measured in triplicates and the mean signals (*A*<sub>490</sub>) are shown over each well area. Rows (A–C), from left to right: β-bungarotoxin, mulgatoxin, taipoxin, crotoxin, crotoxin B, crotoxin A, ammodytoxin A, daboia toxin, mojave toxin B, bovine pancreatic PLA<sub>2</sub>, human synovial fluid, blank. Rows (E–G), from left to right: venoms of *N. siamensis*, *P. australis*, *O. hamnah*, *N. kaouthia*, *B. multicinctus*, *E. carinatus*, *C. rhodostoma*, *D. siamensis* (Myanmar), *D. russelli* (India), *D. pulchella* (Sri Lanka), *D. siamensis* (Thailand), blank.

also reacted strongly with the human synovial fluid collected from arthritic patients.

### The synthetic peptide corresponding to the active site has marked anti-inflammatory activity

The anti-inflammatory effects of P-PB.III, in comparison to those of the full-length recombinant PIP and the anti-inflammatory peptide (antiflammin 2) is reported in Table 2. Co-injection of P-PB.III, either with the venom, toxic PLA<sub>2</sub> (daboia toxin), or the bee venom PLA<sub>2</sub> into the mouse footpad significantly (*P* < 0.01) inhibits the formation of inflammatory oedema over two different dose ranges (50, 100 nmol), with a higher suppression of the inflammatory response seen at a higher dose. In contrast, AIP-2, is less potent than P-PB.III. Comparison of the dose-responses of the recombinant PIP (0.5, 1 nmol) and P-PB.III (50, 100 nmol) by one-way ANOVA shows that there is no significant difference (*P* < 0.05) between the two forms of inhibitor, thus providing evidence that the peptide P-PB.III retains much of the anti-inflammatory property of the intact parent PIP molecule. Although P-PB.III (100 μg) is as potent as PIP (100 μg) on basis of mass, it is much less potent (≈ 100 fold) on a molar basis.

### Intraperitoneal administration of P-PB.III reduces peritoneal tissue PLA<sub>2</sub> activity and modulates peritoneal inflammatory response after surgical trauma

With the aim of investigating the potential therapeutic application of P-PB.III, the effect of the peptide in reducing peritoneal inflammatory response was studied in an *in vivo*

**Table 2. Anti-inflammatory effect of inhibitors on PLA<sub>2</sub>-induced mouse paw oedema.** Experimental details are described in the Experimental procedures. Inhibitory effects were expressed as percentage inhibition of paw oedema, and were assessed by comparing the paw oedema (increase of wt. in mg) of mice receiving (PLA<sub>2</sub> + inhibitor) to those receiving PLA<sub>2</sub> alone. The results (mean ± SD; *n* = 4) were analyzed by a one-tailed Student's *t*-test for groups of unpaired observations (significance taken at minimum of *P* < 0.05). PIP, phospholipase inhibitor from python; P-PB.III, active peptide; AIP-2, anti-inflammatory peptide-2 from Sigma.

Treatment	nmol (μg)	Oedema (mg)	% Inhibition
<i>D.r. siamensis</i> venom	– (5)	117 ± 20	–
+ PIP	1 (100)	29 ± 1 ( <i>P</i> < 0.01)	74.7 ± 0.8
+ P-PB.III	100 (100)	33 ± 6 ( <i>P</i> < 0.01)	71.1 ± 5.5
+ AIP-2	92 (100)	76 ± 11 ( <i>P</i> < 0.05)	35.0 ± 9.7
Daboiatoxin PLA <sub>2</sub>	(1)	166 ± 9	–
+ PIP	0.5 (50)	18 ± 5 ( <i>P</i> < 0.01)	89.2 ± 3.0
+ PIP	1.0 (100)	13 ± 3 ( <i>P</i> < 0.01)	92.2 ± 1.8
+ P-PB.III	50 (50)	63 ± 7 ( <i>P</i> < 0.01)	62.1 ± 4.0
+ P-PB.III	100 (100)	35 ± 6 ( <i>P</i> < 0.01)	79.0 ± 3.6
+ AIP-2	92 (100)	108 ± 11 ( <i>P</i> < 0.01)	35.3 ± 6.5
Bee venom PLA <sub>2</sub>	(1)	89 ± 6	–
+ PIP	0.5 (50)	52 ± 3 ( <i>P</i> < 0.01)	39.9 ± 3.8
+ PIP	1.0 (100)	19 ± 2 ( <i>P</i> < 0.01)	78.1 ± 2.1
+ P-PB.III	50 (50)	42 ± 4 ( <i>P</i> < 0.01)	51.7 ± 4.2
+ P-PB.III	100 (100)	31 ± 4 ( <i>P</i> < 0.01)	63.8 ± 4.8
+ AIP-2	92 (100)	60 ± 7 ( <i>P</i> < 0.01)	33.6 ± 3.9
PIP alone	1.0 (100)	9 ± 8	–
P-PB.III alone	100 (100)	13 ± 2	–
AIP-2 alone	92 (100)	9 ± 4	–

**Table 3. Effect of anti-inflammatory peptides on peritoneal inflammatory response in individual rats after surgical trauma.** Experimental details are described in the Experimental procedures. Values reported are the means ± SD, where *n* = 6–12 rats. One-tailed Student's *t*-test for groups of unpaired observations was done with significance tested at *P* < 0.05; a vs. b, not significant (*P* > 0.05); a vs. c, significant (*P* < 0.05); a vs. d, not significant (*P* > 0.05). The effects of P-PB.III and AIP-2 were confirmed by one-way ANOVA.


Group no.	Rat no.	Adhesion score	
		Grade	Mean ± SD
I (control)	255–266	4	4.0 ± 0 <sup>a</sup> ( <i>n</i> = 12)
II (with gel only)	267	4	3.16 ± 2.82 <sup>b</sup> ( <i>n</i> = 6)
	268	4	
	271	4	
	270	3	
	269	2	
	272	2	
III (with gel + P-PB.III)	275	1	2.00 ± 0.82 <sup>c</sup> ( <i>n</i> = 6)
	276	1	
	278	2	
	273	2	
	274	3	
	277	3	
IV (with gel + AIP-2)	279	4	3.30 ± 1.07 <sup>d</sup> ( <i>n</i> = 6)
	284	4	
	281	4	
	280	3	
	283	3	
	282	2	

incisional hernia model in rats. Most animals in the control group (group I) developed dense adhesions, while in the experimental groups (groups II–IV), relatively fewer post-surgical peritoneal adhesions were seen. Intraperitoneal administration of P-PB.III along with the gel to the site of peritoneal injury significantly reduced the peritoneal inflammatory response with fewer postsurgical adhesions (*P* < 0.05), whereas either the gel alone or the gel with AIP-2, was found to be relatively less potent in reducing the postsurgical peritoneal adhesions. Table 3 depicts adhesion grades in individual rats as analyzed by an independent observer who was blinded about the treatment and nontreatment groups.

At day 7 following surgical trauma, the PLA<sub>2</sub> activity of the peritoneal tissue extracts of control rats markedly increased (*P* = 0.028) over the basal levels found at day 0 (Fig. 4A). In contrast, no significant difference in the peritoneal PLA<sub>2</sub> activity (*P* > 0.05) was found between those two levels (day 0 vs. day 7) in the P-PB.III-treated rats (Fig. 4B). Moreover, when the peritoneal tissue PLA<sub>2</sub> levels of P-PB.III-treated (Fig. 4B) and untreated (Fig. 4A) rats at day 7 following surgical trauma were compared, there was a highly significant difference (*P* = 0.025) observed between the controls and the inhibitor-treated animals (Fig. 4A vs. 4B). These results suggest that the active peptide P-PB.III can afford an effective *in vivo* inhibition of total catalytic PLA<sub>2</sub> activity which is apparently increased as a result of trauma after surgery.

## DISCUSSION

Identification of a protein–protein interaction site is an important step that has significant potential to clarify structure–function relationships of protein and drug designs. Through a survey of a database of protein–protein



**Fig. 4.** Box plots of the PLA<sub>2</sub> activity in extracts of rat peritoneal tissue obtained at the time of surgery (basal) and at day 7 following surgical trauma. (A) Control group ( $N = 6$ ) without P-PB.III treatment; (B) Experimental group ( $N = 6$ ) with P-PB.III treatment. Data are presented as median (solid line across the box), 25th and 75th percentiles. Significant differences are indicated by the  $P$  values. Outliers are represented by circles; open and hatched boxes represent basal and day 7 samples, respectively.

interaction sites, a unique prediction method to identify those sites has previously been proposed, based on the observation that proline is the most common residue found in the flanking segments of interaction sites [28]. In the present study, we have recognized a proline-rich cluster corresponding to residues 85–100 of PIP and other database sequences in the alignment. Because this proline-rich segment is highly conserved amongst members of the snake serum PLI family, it is a distinguishing feature, and is therefore believed to contribute to the biological activity specifically associated with the snake PLI family.

Hence, using the proline bracket method for predicting interaction sites, we have been able to identify the functional site of PIP belonging to the three fingers neurotoxin superfamily. The present findings provide evidence that the mode of interaction between the PLI and the PLA<sub>2</sub> occurs via a common sequence motif represented by the peptide P-PB.III. This decapeptide displays a diverse inhibitory profile against the enzymatic activity of all types of PLA<sub>2</sub>s examined, including that of human secretory PLA<sub>2</sub> present in the synovial fluid of subjects suffering from arthritis. Using a monoclonal antibody specific against human synovial sPLA<sub>2</sub> (Calbiochem, USA), we found that sPLA<sub>2</sub> activity detected in the synovial fluid was inhibited (data not shown), thus confirming that the enzyme contained in the synovial fluid was in fact, a human group II sPLA<sub>2</sub>. To ensure that the inhibition displayed by the active peptide against sPLA<sub>2</sub>s was specific and not artefactual, a dose–response experiment was performed with the peptide P-PB.III, as well as with the control peptide S-P-PB.III, that had scrambled sequence. The peptide P-PB.III inhibited most types of sPLA<sub>2</sub>s examined, including human synovial sPLA<sub>2</sub>, while the scrambled peptide was noninhibitory, confirming that the inhibition was not nonspecific. The active peptide also binds to different sources of PLA<sub>2</sub>s

tested in ELISA. Whatever the species of sPLA<sub>2</sub> origin, the wide spectrum of binding to sPLA<sub>2</sub>s and inhibition of the enzyme activity displayed by the active peptide, coupled with the striking anti-inflammatory effects it possessed, outlines the potential therapeutic usefulness of this inhibitor as an anti-inflammatory agent.

The domain of sPLA<sub>2</sub> or PLI involved in inhibitor binding has yet to be fully elucidated although some structural information suggests that the three-finger motifs of PLIs are important for interaction between  $\gamma$ -type inhibitors and PLA<sub>2</sub>s [35,36]. The broad spectrum of inhibition seen with the PIP-derived peptide in this study suggests that like PIP and other  $\gamma$ -type inhibitors, it could probably recognize the Ca<sub>2</sub><sup>+</sup>-binding loop, which is a common structural element conserved among all groups of secretory PLA<sub>2</sub>s, including human synovial sPLA<sub>2</sub> [37]. Previous data on epitope mapping and studies with synthetic peptides also suggest that the conserved core region of PLA<sub>2</sub> including most of the Ca<sub>2</sub><sup>+</sup>-binding loop may be a potential target for developing selective inhibitors of sPLA<sub>2</sub>s [38]. Based on ELISA results, it appears that P-PB.III binds directly to sPLA<sub>2</sub>, perhaps through the residues on the Ca<sub>2</sub><sup>+</sup>-binding loop. However, it is highly unlikely that its binding to sPLA<sub>2</sub> could involve nonspecific electrostatic interaction, as no charged amino-acid residues, other than the polar and nonpolar residues, are present in the sequence of P-PB.III.

The present results show the oedema-reducing activity of the active peptide, which appears to act via inhibition of PLA<sub>2</sub> activity, and confirms the decapeptide P-PB.III as a potent anti-inflammatory peptide that has potential therapeutic applications, especially for PLA<sub>2</sub>-related inflammatory conditions. The *in vivo* postsurgical peritoneal adhesion model in rats indicates that the intraperitoneal administration of the peptide directly to the site of peritoneal injury can reduce the formation of postsurgical adhesions by a mechanism that could involve inhibition of the activation of endogenous sPLA<sub>2</sub> [2] and through reduction in the peritoneal inflammatory response that occurs after surgery. These results strongly support that the predicted region indeed plays an important role in the interaction between sPLA<sub>2</sub> and the endogenous PLIs of snakes. At present, a crystallographic study is in progress to understand the structural details of PLA<sub>2</sub>–PLI interaction.

## ACKNOWLEDGEMENTS

This work was supported by the Research Grant (R-181-000-025-112) from the National University of Singapore. We are very grateful to Professor Shamal Das De, Department of Orthopaedic Surgery, National University of Singapore, Republic of Singapore, for providing synovial fluid specimens, and also to Professor Kazuki Sato, Fukuoka Women's University, Kasumigaoka, Higashi-ku, Fukuoka, 813–8529, Japan, for the peptides (P-PB.I and S-P-PB.III) used in our study.

## REFERENCES

- Balsinde, J., Balboa, M.A., Insel, P.A. & Dennis, E.A. (1999) Regulation and inhibition of phospholipase A<sub>2</sub>. *Annu. Rev. Pharmacol. Toxicol.* **39**, 175–189.
- Yedgar, S., Lichtenberg, D. & Schnitzer, E. (2000) Inhibition of phospholipase A<sub>2</sub> as a therapeutic target. *Biochem. Biophys. Acta.* **1488**, 182–187.

3. Vadas, P. & Pruzanski, W. (1986) Biology of disease: role of secretory phospholipase A<sub>2</sub> in the pathology of disease. *Lab. Invest.* **55**, 391–404.
4. Murakami, M., Nakatani, Y., Atsumi, G., Inoue, K. & Kudo, I. (1997) Regulatory functions of phospholipase A<sub>2</sub>. *Crit. Rev. Immunol.* **17**, 225–283.
5. Vadas, P., Browning, J., Edelson, J. & Pruzanski, W. (1993) Extracellular phospholipase A<sub>2</sub> expression and inflammation: the relationship with associated disease states. *J. Lipid Med.* **8**, 1–30.
6. Cuella, M.J., Giner, R.M., Recio, M.C., Just, M.J., Manez, S. & Rios, J. (1996) L) Two fungal lanostane derivatives as phospholipase A<sub>2</sub> inhibitors. *J. Nat. Prod.* **59**, 977–979.
7. Matsumoto, K., Tanaka, K., Matsutani, S., Sakazaki, R., Hinoo, H., Uotani, N., Tanimoto, T., Kawamura, Y., Nakamoto, S. & Yoshida, T. (1995) Isolation and biological activity of thielocins: novel phospholipase A<sub>2</sub> inhibitors produced by *Thielavia terricola* RF-143. *J. Antibiotics* **48**, 106–112.
8. Lindahl, M. & Tagesson, C. (1997) Flavonoids as phospholipase A<sub>2</sub> inhibitors: importance of their structures for selective inhibition of group II phospholipase A<sub>2</sub>. *Inflammation* **21**, 347–356.
9. Kogaki, H., Inoue, S., Ikeda, K., Samejima, Y., Omori-Satoh, T. & Hamaguchi, K. (1989) Isolation and fundamental properties of a phospholipase A<sub>2</sub> inhibitor from the blood plasma of *Trimeresurus flavoviridis*. *J. Biochem. (Tokyo)* **106**, 966–971.
10. Inoue, S., Kogaki, H., Ikeda, K., Samejima, Y. & Omori-Satoh, T. (1991) Amino acid sequences of the two subunits of a phospholipase A<sub>2</sub> inhibitor from the blood plasma of *Trimeresurus flavoviridis*. *J. Biol. Chem.* **266**, 1001–1007.
11. Fortes-Dias, C.L., Lin, Y., Ewell, J., Diniz, C.R. & Liu, T.-Y. (1994) A phospholipase A<sub>2</sub> inhibitor from the plasma of the South American rattlesnake (*Crotalus durissus terrificus*). *J. Biol. Chem.* **269**, 15646–15651.
12. Ohkura, N., Inoue, S., Ikeda, K. & Hayashi, K. (1994) The two subunits of the phospholipase A<sub>2</sub> inhibitor from the plasma of Thailand cobra having structural similarity to urokinase-type plasminogen activator receptor and Ly-6 related proteins. *Biophys. Biochem. Res. Commun.* **204**, 1212–1218.
13. Perales, J., Villela, C., Domont, G.B., Choumet, V., Saliou, B., Moussatche, H., Bon, C. & Faure, G. (1995) Molecular structure and mechanism of action of the crotoxin inhibitor from *Crotalus durissus terrificus* serum. *Eur. J. Biochem.* **227**, 19–26.
14. Ohkura, N., Okuhara, H., Inoue, S., Ikeda, K. & Hayashi, K. (1997) Purification and characterization of three distinct types of phospholipase A<sub>2</sub> inhibitors from the blood plasma of the Chinese mamushi, *Agkistrodon blomhoffii sinictus*. *Biochem. J.* **325**, 527–531.
15. Nabuhisa, I., Inamasu, S., Nakai, M., Tatsui, A., Mimori, T., Ogawa, T., Shimohigashi, Y., Fukumaki, Y., Hattori, S., Kihara, H. & Ohno, M. (1997) Characterization and evolution of the gene encoding a *Trimeresurus flavoviridis* serum protein that inhibits basic phospholipase A<sub>2</sub> isozymes in the snake's venom. *Eur. J. Biochem.* **249**, 838–845.
16. Lizano, S., Lomonte, B., Fox, J.W. & Gutierrez, J.M. (1997) Biochemical characterization and pharmacological properties of a phospholipase A<sub>2</sub> myotoxin inhibitor from the plasma of the snake *Bothrops asper*. *Biochem. J.* **326**, 853–859.
17. Okumura, K., Ohkura, N., Inoue, S., Ikeda, K. & Hayashi, K. (1998) A novel phospholipase A<sub>2</sub> inhibitor with leucine-rich repeats from the blood plasma of *Agkistrodon blomhoffii sinictus*. Sequence homologies with human leucine-rich A<sub>2</sub>-glycoprotein. *J. Biol. Chem.* **273**, 19469–19475.
18. Ohkura, N., Kitahara, Y., Inoue, S., Ikeda, K. & Hayashi, K. (1999) Isolation and amino acid sequencing of the phospholipase A<sub>2</sub> inhibitor from the blood plasma of the sea krait, *Laticauda semifasciata*. *J. Biochem. (Tokyo)* **125**, 375–382.
19. Hains, P.G., Sung, K.-L., Tseng, A. & Broady, K.W. (2000) Functional characteristics of a phospholipase A<sub>2</sub> inhibitor from *Notechis ater* serum. *J. Biol. Chem.* **275**, 983–991.
20. Hains, P.G. & Broady, K.W. (2000) Purification and inhibitory profile of phospholipase A<sub>2</sub> inhibitors from Australian elapid sera. *Biochem. J.* **346**, 139–146.
21. Okumura, K., Masui, K., Inoue, S., Ikeda, K. & Hayashi, K. (1999) Purification, characterization and cDNA cloning of a phospholipase A<sub>2</sub> inhibitor from the serum of the non-venomous snake *Elaphe quadrivirgata*. *Biochem. J.* **341**, 165–171.
22. Thwin, M.-M., Gopalakrishnakone, P., Kini, R.M., Armugam, A. & Jayaseelan, K. (2000) Recombinant antitoxic and anti-inflammatory factor from the nonvenomous snake *Python reticulatus*. phospholipase A<sub>2</sub> inhibition and venom neutralizing potential. *Biochemistry* **39**, 9604–9611.
23. Noel, L.S., Champion, B.R., Holley, C.L., Simmons, C.J., Morris, D.C., Payne, J.A., Lean, J.M., Chamber, T.J., Zaman, G., Lanyon, L.E., Suva, L.J. & Miller, L.R. (1998) RoBo-1, a novel member of the urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family selectively expressed in rat bone and growth plate cartilage. *J. Biol. Chem.* **273**, 3878–3883.
24. Miele, L., Cordella-Miele, E., Facchiano, A. & Mukherjee, A.B. (1988) Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. *Nature* **335**, 726–730.
25. Rodgers, E.E., Girgis, W., Campeau, J.D. & diZerega, G.S. (1997) Reduction of adhesion formation by intraperitoneal administration of anti-inflammatory peptide 2. *J. Invest. Surg.* **10**, 31–36.
26. Marastoni, M., Scaranari, V., Romualdi, P., Donatini, A., Ferri, S. & Tomatis, R. (1993) Studies on the anti-phospholipase A<sub>2</sub> and anti-inflammatory activities of a uteroglobin fragment and related peptides. *Arzneim. Forsch/Drug Res.* **43**, 997–1000.
27. Hope, W.C., Patel, B.J. & Bolin, D.R. (1991) Antiflammin-2 (HDMNKVLDL). does not inhibit phospholipase A<sub>2</sub> activities. *Agents Actions* **34**, 77–80.
28. Kini, R.M., Caldwell, R.A., Wu, Q.Y., Baumgarten, C.M., Feher, J.J. & Evans, H.J. (1998) Flanking proline residues identify the I-type CA<sub>2</sub><sup>+</sup> channel binding site of calciseptine and FS2. *Biochemistry* **37**, 9058–9063.
29. Council for International Organizations of Medical Sciences (CIOMS) (1985) International Guiding Principles for Biomedical Research involving Animals. *The WHO Chronicle* **39**, 51–56.
30. Elsbach, P. & Weiss, J. (1991) Utilization of labeled *Escherichia coli* as phospholipase substrate. In *Methods in Enzymology. Phospholipases* (Dennis, E.A., ed.), Vol. 197, pp. 24–31. Academic Press Inc., San Diego, CA.
31. Yamakawa, M., Nozaki, M. & Hokama, Z. (1976) Fractionation of Sakishmma-habu (*Trimeresurus elegans*) venom and lethal hemorrhage and oedema forming activity of the fractions. In *Animal, Plant and Microbial Toxins* (Ohsaka, A., Hayashi, K. & Sawai, Y., eds), Vol. 1, pp. 97–103. Plenum Press, New York.
32. diZerega, G.S. & Rodgers, K.E. (1992) Intraperitoneal adhesions. In *The peritoneum*, pp. 274–306. Springer, New York.
33. Alponat, A., Lakshminarasappa, S.R., Teh, M., Rajnakova, A., Moochhala, S., Goh, P.M. & Chan, S.T. (1997) Effects of physical barriers in prevention of adhesions: an incisional hernia model in rats. *J. Surg. Res.* **68**, 126–132.
34. Bradford, M.M. (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. *Anal. Biochem.* **72**, 248–254.
35. Nabuhisa, I., Chiwata, T., Fukumaki, Y., Hattori, S., Shimohigashi, Y. & Ohno, M. (1998) Structural elements of *Trimeresurus flavoviridis* serum inhibitors for recognition of its venom phospholipase A<sub>2</sub> isozymes. *FEBS Lett.* **429**, 385–389.



36. Faure, G. (2000) Natural inhibitors of toxic phospholipase A<sub>2</sub>. *Biochimie* **82**, 833–840.
37. Inoue, S., Shimada, A., Ohkura, N., Ikeda, K., Samejima, Y., Omori-Satoh, T. & Hayashi, K. (1997) Specificity of two types of phospholipase A<sub>2</sub> inhibitors from the plasma of venomous snakes. *Biochem. Mol. Biol. Int.* **41**, 529–537.
38. Cordella-Miele, E., Miele, L. & Mukherjee, A.B. (1993) Identification of a specific region of low molecular weight phospholipase A<sub>2</sub> (residues 21–40) as a potential target for structure-based design of inhibitors of these enzymes. *Proc. Natl Acad. Sci. USA* **90**, 10290–10294.